Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 52 INDUSTRY 45 OTHER_GOV 3 NIH 2 NETWORK 1 INDIV 1 FED 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7 Barrett Esophagus 5 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Multiple Myeloma 2 Lymphoma, Follicular 2 Lipoma 2 Leiomyoma 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma in Situ 2 Warts 1 Vaginosis, Bacterial 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Syphilis 1 Sexually Transmitted Diseases 1 Retroperitoneal liposarcoma 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pilonidal Sinus 1 Papillomavirus Infections 1 Overweight 1 Ovarian Neoplasms 1 Osteosarcoma 1 Obesity 1 Neutropenia 1 Neoplasms, Squamous Cell 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Melanoma 1

Interventions

ethyl pyruvate 1 compound W 1 Salicylates 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDIV × Interventional × Warts × Clear all

NCT01712295 2012-10-23

17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts

Grossman, Michael, D.P.M.

Phase 4 Unknown

Warts

Data powered by HemOnc (CC BY 4.0) Colophon ⚡